USFDA warning letter resolution delay
USFDA warning letter at Bangalore site continues to impact CDMO growth and new customer onboarding. Management expects resolution by end of FY27 but timeline uncertain.
HIKAL / Q4-FY26 / risks
Keep the risk register visible.
Hikal · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Raw material cost inflation and pass-through lag
Solvent prices have surged due to geopolitical tensions; pass-through mechanisms have a lag of one quarter, potentially impacting Q1 FY27 margins.
Impairment of multipurpose agrochemical facility
Company took a ₹47 crore impairment on a multipurpose agrochemical plant being retooled for pharma, indicating past capex inefficiencies.